Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 11/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12265061 | 1.00 | PPARA (0.53) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL22506799 | 1.00 | PPARA (0.53) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL22092038 | 0.85 | CTSS (0.56) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL22092039 | 0.85 | CTSS (0.56) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL27344128 | 0.83 | PPARA (0.49) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL27343574 | 0.83 | PPARA (0.49) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL23743602 | 0.83 | CTSK (0.43) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL13622615 | 0.82 | CA1 (0.44) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL25315586 | 0.82 | CA1 (0.44) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL19361663 | 0.82 | CA1 (0.44) | PPARACTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | PPARA 4777/4885PPARG 4787/4885CTSS 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.